Three‐year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus‐eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus‐eluting stent: A randomized controlled trial-Reference-Cited by-同舟云学术

Three‐year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus‐eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus‐eluting stent: A randomized controlled trial

Published:2019-12-20 Issue:7 Volume:96 Page:1399-1406
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Catheter Cardiovasc Interv

Author:

Kim Soo‐Hyun¹,Kang Si‐Hyuck¹^ORCID,Lee Joo Myung²^ORCID,Chung Woo‐Young³^ORCID,Park Jin Joo¹,Yoon Chang‐Hwan¹,Suh Jung‐Won¹,Cho Young‐Seok¹,Doh Joon‐Hyung⁴,Cho Jin Man⁵,Bae Jang‐Whan⁶,Youn Tae‐Jin¹^ORCID,Chae In‐Ho¹

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, College of Medicine Seoul National University and Cardiovascular Center, Seoul National University Bundang Hospital Seongnam‐si Gyeonggi‐do Republic of Korea

2. Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea

3. Department of Internal Medicine Boramae Medical Center Seoul Republic of Korea

4. Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital Goyang Gyeonggi‐do Republic of Korea

5. Division of Cardiology, Department of Internal Medicine Kyung Hee University Hospital at Gangdong Seoul Republic of Korea

6. Department of Internal Medicine, College of Medicine Chungbuk National University Cheongju Republic of Korea

Funder

Biotronik Korea Co., Korea

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.28654

Reference36 articles.

1. Drug‐eluting or bare‐metal stents for coronary artery disease;Nordrehaug JE;N Engl J Med,2016

2. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary

3. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds

4. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

5. 2018 ESC/EACTS Guidelines on myocardial revascularization

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of ultrathin vs. standard strut drug-eluting stents: insights from a large-scale meta-analysis with extended follow-up;European Journal of Medical Research;2024-07-27

2. Final 5‐year report of BIONYX comparing the thin‐composite wire‐strut zotarolimus‐eluting stent versus ultrathin‐strut sirolimus‐eluting stent;Catheterization and Cardiovascular Interventions;2024-05-07

3. Comparative Effectiveness of Ultrathin vs. Standard Strut Drug-Eluting Stents: Insights from a Large-Scale Meta-Analysis with Extended Follow-up;2024-04-01

4. Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents;Indian Heart Journal;2023-07

5. Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?;Journal of Personalized Medicine;2023-04-28